Efficacy and Safety of AEB071 Versus Tacrolimus in Combination With Mycophenolate Acid Sodium, Basiliximab and Steroids in Preventing Acute Rejection After Kidney Transplantation
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Inclusion:
Male and female patients of any race 18 years or older
Adult recipients of kidney transplant from a deceased or living donor
Recipients of a functioning kidney within 24 hours post transplant
Exclusion:
Need for medication prohibited by the protocol
Patients or donors infected with Hepatitis B,C or HIV
Patients with a history of cancer within last 5 years
Patients with history of significant cardiac disorder
Patients of high-risk immunological status
Clareo Health | Efficacy and Safety of AEB071 Versus Tacrolimus in Combination With Mycophenolate Acid Sodium, Basiliximab and Steroids in Preventing Acute Rejection After Kidney Transplantation
